title: Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
abstract: BACKGROUND
  We performed a systematic review and meta-analysis to determine the risk of mucocutaneous adverse events associated with lapatinib.
  
  
  METHODS
  Eligible studies included randomized phase II and III trials of patients with solid tumors on lapatinib; describing events of stomatitis, skin rash, hand foot syndrome, pruritus and alopecia.
  
  
  RESULTS
  Our search strategy yielded 380 potentially relevant citations on lapatinib from PubMed/Medline, CENTRAL Cochrane Registry and ASCO Meeting Library. After exclusion of ineligible studies, a total of 19 clinical trials were considered eligible for the meta-analysis. The RRs of all-grade skin rash, stomatitis, hand foot syndrome and pruritus were 3.04 (95% CI 2.33-3.96; p < 0.00001), 1.67 (95% CI 1.02-2.3; p < 0.04), 4.45 (95% CI 1.15-17.19; p = 0.03), and 2.02 (95% CI 1.46-2.8; p < 0.0001), respectively. Exploratory subgroup analysis showed no effect of treatment regimen on the RRs of the relevant adverse events.
  
  
  CONCLUSIONS
  Our meta-analysis has demonstrated that lapatinib is associated with a significantly increased risk of all-grade skin rash, hand foot skin reaction and pruritus. Clinicians should be aware of these risks and perform regular clinical monitoring.
authors.affiliation: Clinical Oncology Department, Faculty of Medicine, Ain Shams University , Cairo , Egypt.
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Rahman
authors.forename: Mona
authors.initials: M
authors.lastname: Fouad
mesh_terms: D000505:Alopecia / Q000139:chemically induced / Q000453:epidemiology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D060831:Hand-Foot Syndrome / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D000077341:Lapatinib; D009369:Neoplasms / Q000188:drug therapy*; D011537:Pruritus / Q000139:chemically induced / Q000453:epidemiology; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012306:Risk
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib
keywords: Lapatinib; Meta-analysis; Skin rash; Stomatitis